Introduction
Breast cancer remains a major public health concern in the United States and is the second highest cause of cancer death in women. It is estimated that in 2005 over 200 000 women will develop breast cancer and 40 400 will die of their disease (Jemal et al., 2005) . The estrogen receptor (ER) regulates growth and differentiation of the normal mammary gland and is important in the development and progression of about 70% of breast cancer. Like other steroid hormone receptors, the ER mediates its downstream effects by direct transcriptional regulation of target genes (Gruber et al., 2002; McKenna and O'Malley, 2002) . In recent years, alternative ER signaling via direct association with and activation of many signal transduction pathways has been described (Cato et al., 2002; Losel et al., 2003) . For several decades, targeting the ER has been the cornerstone in treatment for ER-positive (ER( þ )) breast cancer (Mouridsen et al., 2001; Goss et al., 2003; Smith and Dowsett, 2003; Osborne et al., 2004; Tobias, 2004; Howell et al., 2005) .
ER-negative, progesterone receptor-negative (ER(À)/ PR(À)) breast cancer represents approximately 25-30% of all breast cancers and generally has a more aggressive clinical course. In contrast to ER( þ ) breast cancer, patients with ER(À)/PR(À) tumors derive little or no benefit from anti-estrogen therapy (Howell et al., 2005) and targeted therapies remain elusive (Slamon et al., 2001) . One notable exception has been the successful use of antibodies targeting the tyrosine kinase receptor HER-2-neu (ERBB2), which is disproportionably overexpressed in ER(À) breast cancer (Slamon et al., 2001; Lal et al., 2005) . In addition to ER, breast cancer cells express other nuclear hormone receptors. For example, the androgen receptor (AR) is expressed in 60-80% of breast cancers and implicated in breast cancer biology (Isola, 1993) . Recent studies have reported that among postmenopausal women, high androgen levels are associated with an increased risk of developing breast cancer (Agoff et al., 2003) . Furthermore, androgens can induce proliferation in breast tissue, and initiate tumor formation via the AR in animal models (Wong and Xie, 2001) . The mechanisms by which the AR contributes to the initiation and progression of breast cancer and its functional relationship to the ER are unknown. It also remains to be determined if targeting the AR could extend the benefits of hormonal therapy to women with ER(À)/PR(À), AR-positive breast cancer.
Genome-wide transcript analysis using DNA microarray technology is an important and well-established new tool in the study of human disease. The technology allows the measurement of several thousands of mRNA species simultaneously. The resulting gene expression profiles have been used to distinguish tumor classes not evident by traditional methods (DeRisi et al., 1996; Golub et al., 1999) . In breast cancer, DNA microarray analysis has demonstrated that ER( þ ) breast cancer and ER(À)/PR(À) disease have unique molecular profiles, has identified several distinct molecular subclasses and has been used to predict disease recurrence (Perou et al., 2000; Gruvberger et al., 2001; West et al., 2001; van't Veer et al., 2002; Pusztai et al., 2003) . Few reports specifically focus on gene expression analysis of ER(À)/PR(À) breast cancers and are limited by small sample size (Nagahata et al., 2004) . We carried out transcript profiling of human breast cancers and focused attention on ER(À) tumors in an effort to better define important biological subsets. We report the identification of a previously uncharacterized ER(À)/PR(À) breast cancer subset with a hormonally regulated gene expression signature and AR-dependent, androgeninduced cell growth in culture. This represents a clinically relevant subset of ER(À)/PR(À) breast cancer for which AR may provide a useful therapeutic target.
Results

Molecular heterogeneity of ER(À)/PR(À) breast cancers demonstrated by genome-wide expression analysis
In order to explore the molecular heterogeneity of breast cancers, we performed genome-wide transcript profiling for 99 primary breast carcinomas using oligonucleotide microarrays. In all cases, we performed immunohistochemical assessment of ER and PR to ensure the accuracy of receptor status and determine heterogeneity. Forty-one tumors were ER(À)/PR(À), two were ER(À)/ PR( þ ) and 56 were ER( þ ). There was a close correspondence between the transcript level for ER determined by microarray and ER protein expression determined by a semiquantitative immunohistochemistry (IHC) score (% immunoreactive cells times intensity, spearman's r ¼ 0.834, Po0.01).
Unsupervised hierarchical clustering revealed a strong association between ER status and molecular profile as previously reported (Gruvberger et al., 2001) . However, nine ER(À)/PR(À) breast cancers were grouped with the ER( þ ) tumors and three ER( þ ) samples were grouped with ER(À)/PR(À) breast cancers (Figure 1 ). The finding of breast cancers molecularly discordant with ER status suggested heterogeneity within the major breast cancer subtypes and was further explored.
We focused on ER(À)/PR(À) breast cancers and performed unsupervised hierarchical clustering limited to the 41 ER(À)/PR(À) tumors. Of the major clusters in the dendrogram, it was of particular interest that the nine ER-discordant samples identified in the previous analysis were all closely correlated and contained in a single cluster with only one additional case (Figure 2a) . To evaluate the reproducibility of these molecular subgroups, we used a principal component analysis (PCA) to plot ER(À)/PR(À) samples in three dimensions. These same 10 samples were distinct from the other ER(À)/PR(À) samples, demonstrating relatively robust molecular phenotypes (Figure 2b ). Therefore, within our sample set of ER(À)/PR(À) breast cancers, we detected two major molecular subdivisions: one composed of 10 samples with a molecular resemblance to ER( þ ) breast cancer (referred to hereafter as ER(À) class A) and another composed of the remaining 31 breast cancers (ER(À) class B).
Characterization of genes differentially expressed in ER(À)/PR(À) breast cancer subtypes By visual inspection of two-dimensional cluster diagrams, it was evident that a number of genes differentially expressed in ER(À) class A relative to other ER(À)/PR(À) breast cancers are similarly expressed in ER( þ ) tumors (Figure 1 ). These initial observations suggested that ER(À) class A tumors expressed a molecular signature common to ER( þ ) breast cancers. To further evaluate this finding, we first identified 202 genes markedly differentially expressed according to ER status (at least threefold difference between the means of ER( þ ) and ER(À)/PR(À) cases and a Student's t-test Po0.0001) (Supplementary Table 2 ). Not surprisingly, many of the differentially expressed genes have been identified in previous similar analyses (Gruvberger et al., 2001; West et al., 2001 ). We next identified 138 genes significantly differentially expressed between ER(À)/ PR(À) class A and class B samples. Ninety-six genes were overexpressed and 42 genes were underexpressed in class A relative to class B. Of the 96 genes differentially overexpressed in class A, 15 have been reported to be experimentally valid direct targets of the ER (Tang et al., 2004; Laganiere et al., 2005) , 12 were responsive to estrogen in a previous genome-wide molecular study (Cunliffe et al., 2003) and 24 genes were differentially overexpressed in ER( þ ) tumors compared to all ER(À)/PR(À) tumors in our data (Table 1) . The number of genes common among the 96 overexpressed genes in class A and each gene set described above was much greater than expected by chance (Po0.0001). Among the 42 genes underexpressed in ER(À) class A, three genes have been identified as experimental targets of the ER (Tang et al., 2004; Laganiere et al., 2005) (P ¼ 0.065), and five genes were differentially underexpressed in ER( þ ) tumors compared to all ER(À)/ PR(À) tumors in our data (Po0.0001). The data strongly suggest that ER(À) class A was distinguished from class B by expression of a transcriptional program that is associated with ER( þ ) breast cancer.
To explore the potential of the differentially expressed genes as direct targets for steroid hormone receptors, we searched 5 kb of DNA sequence 5 0 of the transcription start site for putative AR and ER response elements (ARE, ERE) in each of the 138 genes. Among the 96 genes overexpressed in class A, 24 had promoter regions containing at least one putative ERE, and 13 had promoter regions with at least one putative ARE.
Among the 42 genes underexpressed in class A, four genes had promoter regions containing at least one putative ERE, and two genes had promoter regions containing at least one putative ARE (Po0.0001 for both ERE and ARE). These observations suggested that ER(À) class A breast cancer more closely resembled an ER( þ ) breast cancer molecular phenotype owing to expression of many hormonally regulated genes that are based on data from several lines of investigation.
In order to further evaluate this finding, we obtained unigene id numbers for 386 estrogen responsive genes identified in a previously published genome-wide expression analysis using an experimental platform different from that used in our study (Cunliffe et al., 2003) , and identified 508 corresponding Affymetrix probe sets. Cluster analysis limited to this set of genes tended to group ER(À) class A samples intermediately between ER( þ ) samples and the remaining ER(À)/PR(À) tumors (Supplementary Figure 1) . This was also true for the ER(À) class A cell line, as described below. This provides an independent confirmation that ER(À) class A breast cancers were characterized by expression of gene profiles that are similar to those of ER( þ ) tumors.
Immunohistochemical analysis of gene transcript differences between ER(À)/PR(À) breast cancer subtypes In order to further evaluate and validate the molecular differences identified by the genome-wide expression analysis, we performed IHC for proteins expected to be differentially expressed between ER(À) class A and ER(À) class B based on transcript analysis. Genes with a high magnitude of differential expression between ER(À) subtypes, for which useful antibody reagents were available, and those of known functional significance in breast cancer were studied (Table 1) . Protein expressions of ALCAM and SPDEF were analysed on a continuous scale using an IHC score (percentage of cells staining times intensity). There was significant differential protein expression between ER(À) class A and ER(À) class B samples for both (P ¼ 0.023 and Po0.0001, respectively) ( Figure 3) . A significant proportion of ER(À) class A samples were immunoreactive for the AR and FOXA1 compared to ER(À) class B samples (50 vs 16%, P ¼ 0.045 and 70 vs 9%, P ¼ 0.0005, respectively) in concordance with transcript levels. Unique estrogen receptor-negative breast cancer subtype AS Doane et al
We also evaluated two breast cancer-associated proteins that may participate in the regulation of hormonally responsive gene expression, ERBB2 and ERb. The proportion of ERBB2-positive samples for ER(À) class A and ER(À) class B was 0.30 and 0.15 respectively, and was in good agreement with the ERBB2 transcript levels. By IHC, luminal epithelial cells of non-neoplastic breast expressed moderate levels of ERb; however, there was little or no ERb protein expression detected in any of the ER(À)/PR(À) samples.
Because several genes differentially expressed in ER(À) class A were identifiable at the protein level by IHC in formalin-fixed, paraffin-embedded (FFPE) tissue sections, we evaluated the feasibility of developing a combination of IHC markers for routine clinical identification of ER(À) class A breast cancers. A combination of ER, PR, SPDEF and ALCAM was estimated to predict ER(À)/PR(À) samples as class A with a sensitivity approaching 100% (95% CI 69-100%), and a specificity of 94% (95% CI 79-99%). It is Unique estrogen receptor-negative breast cancer subtype AS Doane et al Unique estrogen receptor-negative breast cancer subtype AS Doane et al important to note that our analysis is limited by sample size and lack of independent validation, and therefore may overestimate the predictive value. The practical utility of an IHC assay for class distinction requires further study.
Class prediction and independent evaluation of ER(À) breast cancer subsets
In order to determine if the ER(À) class A subclass was a reproducible finding and identify appropriate breast cancer cell lines for further study, we developed a knearest neighbor classification model using genes that were differentially expressed (P-value o0.0001) between ER(À) class A and all other ER(À)/PR(À) tumors. We applied this classification method to an independent, publicly available breast cancer gene expression data set that used the same analytical platform (Wang et al., 2005) . A similar proportion of ER(À)/PR(À) samples was classified as ER(À) class A in this independent data set as in our samples (32 vs 24%). Many of the genes differentially expressed in the comparison of ER(À) class A and ER(À) class B in our original data were also differentially expressed in the independent predicted subsets. AR, CYB5, XBP1, FOXA1 and SPDEF, as well as the androgen responsive genes APOD (Hall et al., 1996) and PIP (Carsol et al., 2002) , were among the top 50 significantly overexpressed genes in the predicted class A (Po1eÀ10). In addition, ERBB2 and FGFR4 were overexpressed in the predicted ER(À) class A of the independent data with a higher degree of significance than in our original sample set (P ¼ 1.6eÀ14 and P ¼ 1.4eÀ08, respectively). Not only was the ER(À) class A clearly distinguishable in the independent data by supervised analysis, but unsupervised approaches indicated that these classes represent a primary distinction among ER(À)/PR(À) tumors. An unsupervised hierarchical clustering of the 77 ER(À)/PR(À) tumors yielded primary groups of samples, which corresponded very closely to the class prediction assignments by the predictive model (Figure 4 ). Although the independent samples were not available for confirmation of ER status or further analyses, the data from class prediction and unsupervised clustering provided further evidence that the ER(À) class A and B distinction was reproducible and intrinsic to the primary molecular substructure of ER(À)/PR(À) tumors.
We then used the prediction model to evaluate breast cancer cell lines in order to identify cell lines corresponding to the ER(À) class A molecular phenotype. Expression profiles were generated for the ER(À)/PR(À) cell lines MDA-MB-231, MDA-MB-453, HCC-1937 and SKBR-3. These cell lines have been described to represent important distinctions within the spectrum of ER(À)/ PR(À) disease (Lacroix and Leclercq, 2004) . Our classification model identified the cell line MDA-MB-453 as The ER(À) class A cell line MDA-MB-453 shows a proliferative response to androgen that is AR dependent and ER independent The identification of ER(À)/PR(À) breast tumors characterized by expression profiles including estrogenregulated genes suggested an ER-independent mechanism for activation of hormonally responsive transcription that contributed to tumor growth and survival. In order to define the mechanism for regulation of this transcriptional program, we first sought to determine whether low levels of active ER, below the limit of detection in clinical assays, might be contributing to growth of ER(À) class A tumors. In our group A model cell line MDA-MB-453, ER transcript levels were very low with an absolute adjusted intensity of 38.0 and Affymetrix MAS 5.0 call of absent. Incubation with 100 nM E2 had no effect on cell culture growth compared to vehicle control. Accordingly, incubation with either the pure anti-estrogen ICI or tamoxifen, Figure 4 Reproducibility of ER(À) breast cancer subclasses. Two-way hierarchical clustering was performed with 77 ER(À) breast tumors from an independent data set using 1262 genes with greatest variance across samples. The resulting dendrogram revealed a tendency to group samples according to our class prediction assignments. A strongly differentially expressed gene cluster is enlarged and genes associated with ER status and class A are labeled.
Unique estrogen receptor-negative breast cancer subtype AS Doane et al alone or in combination with 100 nM E2, had no effect on overall cell viability compared to vehicle control (Figure 5a ). This is in contrast to the ER( þ ) cell line MCF-7 that was markedly growth stimulated by administration of 100 nM E2, and this effect was abrogated by the addition of the pure anti-estrogen ICI (data not shown). These results suggested that the ER was not playing an active role in the growth and survival of ER(À) class A breast cancer cells.
Because there is the potential for functional overlap of transcriptional regulation by steroid hormone receptors, we reasoned that other nuclear receptors might play a role in ER(À) class A breast cancers. We examined the expression of many known nuclear hormone receptors, including ER-b, ESRRA, PR, AR, RARA, RXRA, GCHR, PPAR and VDR and found that the AR was the only nuclear hormone receptor differentially overexpressed in ER(À) class A. The AR has been implicated in the pathogenesis of breast cancer (Wong and Xie, 2001) , and it is known to activate a number of estrogen responsive genes (Nantermet et al., 2005) . Incubation with the synthetic non-metabolizable androgen R-1881 at concentrations between 0.1 and 10 nM stimulated growth in MDA-MB-453. This proliferative effect was abrogated by the addition of the AR antagonist flutamide, confirming that the response was AR dependent (Figure 5b) . Again, we determined that the effects of androgen were not dependent on the ER, as MDA-MB-453 cells treated with androgens in combination with the anti-estrogens tamoxifen or ICI had minimal effect on the androgen-induced proliferation (Figure 5c ). These observations indicated that AR signaling was intact in ER(À) class A breast cancer cells, and that cell growth and survival were responsive to androgen in an AR-dependent, ER-independent manner.
The ER(À) class A molecular phenotype is associated with androgen responsive genes Because the ER(À) class A cell line MDA-MB-453 demonstrated a proliferative response to androgen, we set out to determine whether this was associated with the transcriptional program characteristic of ER(À) class A human breast cancers. We monitored gene expression changes after administration of androgens, androgen antagonists or vehicle control to the ER(À) class A cell line MDA-MB-453 under a variety of growth conditions (see Materials and methods). The results of the various experiments were concordant, but the most pronounced differences in gene expression were observed between those cells first incubated in steroid-deprived conditions for 48 h, and then treated with either R-1881 or vehicle for 48 h. After trimming to eliminate genes with very low-level expression (o200 in both conditions), 497 genes were differentially expressed by at least twofold between cells exposed to R-1881 or vehicle. The androgen-regulated gene SARG was upregulated by 247-fold, and has been previously shown to contain an experimentally verified, hormonally active androgen response element (Steketee et al., 2004) . Several other androgen responsive genes including FASN, NDRG1 and SORD each contain putative androgen response elements in their promoters (Nelson et al., 2002; Dhanasekaran et al., 2005) , and were highly upregulated after administration of R-1881. Furthermore, FASN, NDRG1 and SORD are implicated in the androgenmediated development of prostate cancer (Shurbaji et al., 1996; Rossi et al., 2003) , and their expression levels are positively correlated with the expression of prostate-specific antigen in human prostate cancer cells (Nelson et al., 2002) . These observations provided indirect evidence that administration of R-1881 to MDA-MB-453 caused recruitment of an active AR transcription complex to highly specific AREs.
To evaluate the association between androgen responsive genes in MDA-MB-453 and the ER(À) class A molecular phenotype, we compared androgen-induced gene expression changes to genes differentially expressed between ER(À) classes A and B. Of the 497 differentially expressed genes between cells treated with R-1881 or vehicle control, 22 were common to our ER(À) class A expression signature, and this number of commonly expressed genes was highly significant (P ¼ 3eÀ8) (Supplementary Table 3 ). In particular, ALCAM was overexpressed in cells treated with R-1881 compared to cells treated with vehicle control, and was also significantly overexpressed at the protein and transcript levels in class A breast cancers, as described above. Therefore, the genes that comprise the ER(À) class A molecular fingerprint were at least in part androgen responsive in the class A cell line.
To further explore the association between the ER(À) class A molecular phenotype and an androgen-dependent transcription program, we performed PCA of the 41 ER(À)/PR(À) breast tumors using the 497 androgen responsive genes and plotted samples based on three principal components. The ER(À) class A and B samples formed distinct clusters (Figure 6a ). Furthermore, the same approach using the 77 ER(À)/PR(À) samples from the independent data set demonstrated clusters corresponding to our class predictions Figure 6 Molecular subclasses of ER(À) breast cancer based on androgen responsive genes. Three-dimensional plot of the three principal components with the greatest variance across 41 ER(À)/ PR(À) primary breast tumors using 497 genes responsive to androgen in the class A cell line MDA-MB-453. (b) Threedimensional plot of the three principal components with the greatest variance among 77 ER(À) breast tumors from an independent data set using the 497 androgen responsive genes. Samples are colored according to class prediction assignments.
Unique estrogen receptor-negative breast cancer subtype AS Doane et al (Figure 6b ). We next used a weighted KolmogorovSmirnov (KS) statistic (Subramanian et al., 2005) to evaluate the degree to which the 497 androgen-regulated genes were correlated with the ER(À) class A and B distinction. The results indicated that among the original and independent data sets, tumors designated as ER(À) class A were significantly enriched in androgenregulated genes (Po0.0001 for both data sets) (Supplementary Figures 2A and B) . These results suggested that the ER(À) class A molecular phenotype was partially recapitulated by the expression of genes regulated by androgen in ER(À) class A breast cancer cells.
We also determined whether genes induced by androgens in MDA-MB-453 corresponded to the transcriptional program activated by estrogens in ER( þ ) breast cancer cells and therefore could contribute to the molecular relationship between ER(À) class A and ER( þ ) breast cancers. Fifty of the 497 androgen responsive genes from our experiments were in common with the 386 estrogen responsive genes determined by an independent study using MCF7, T-47D and MDA-MB-436 breast cancer cells (P ¼ 4eÀ16) (Cunliffe et al., 2003) . Therefore, androgen induced a transcriptional program in AR-positive ER(À) class A breast cancer that significantly overlapped with that induced by estrogen in ER( þ ) breast cancer.
Discussion
Clinicians have long recognized that the current classification of breast cancer based on histopathological grade, hormone receptor status and HER2 status does not sufficiently capture the clinical and biologic heterogeneity observed in practice. This has fueled efforts to develop more biologically and clinically meaningful classification based on molecular features. We applied unsupervised and supervised analyses to gene expression profiles of primary breast cancers, and identified a subset of ER(À)/PR(À) tumors with a molecular signature that suggests an active hormonally regulated transcriptional program. Gene expression signatures were used to develop a predictive model that identified this subset among independent tissue samples and breast cancer cell lines. The breast cancer cell line MDA-MB-453 recapitulated the molecular phenotype and was used to investigate the biological basis for this subclass. Several molecules that can initiate signal transduction contributing to tumor growth and survival were overexpressed in this tumor subset, including AR, ERBB2 and FGFR4. We found that androgen enhanced growth of MDA-MB-453 in an ER-independent but AR-dependent manner. In addition, the ER(À) class A molecular phenotype was at least partially androgen regulated. Taken together, our findings help to define a distinctive molecular subset of ER(À)/PR(À) breast cancer with the potential for novel targeted therapeutic strategies.
The potential for molecular subclassification of breast cancers based on genome-wide expression analysis has been well documented in previous studies. Applying a class discovery approach using cDNA microarrays, Perou et al. (2000) identified at least five molecular subtypes of breast cancer (termed luminal subtypes A and B, ERBB2, basal and normal breast like) based on expression of an internally derived 'intrinsic' gene list. These subtypes have been repeatedly observed across various high-throughput platforms (Sorlie et al., 2003; Wilson and Dering, 2004) . The luminal subtype A and basal groups are the most robust in independent data analysis. This luminal subtype is primarily composed of ER( þ ) tumors, generally demonstrates a better prognosis and is characterized by relative overexpression of estrogen-related genes such as GATA3, XBP1, FOXA1, CCDN1, TFF3 and ERa. The basal class is so named because its expression pattern resembles that of the basal epithelial cell component of the breast including lack of expression of ER and related genes, and expression of cytokeratins 5/6 and 17. Hierarchical clustering of our data using the intrinsic gene list revealed that the luminal A and basal subtypes were evident, whereas the remaining subtypes were not nearly as distinct (Supplementary Figure 3) . This is similar to previous reports and suggests that other subtypes of breast cancer require refinement of their molecular definition (Sorlie et al., 2003; Wilson and Dering, 2004) . The ER(À) class A samples described here are distinct from the luminal A and basal subtypes. This subset is most distinct when clustering is not limited to the intrinsic gene set of Perou and even more so when the analysis is limited to ER(À) breast cancers. Our data suggest that ER(À) class A breast cancers bear a much closer molecular relationship to ER( þ ) breast cancers than to the basal subtype despite the shared ER(À) phenotype. This observation was recapitulated in a larger independent sample of 77 ER(À) breast cancers. This work serves to better define a previously unrecognized breast cancer subset, with important implications for the diagnosis and treatment of women with ER(À)/ PR(À) breast cancer.
Our results suggest that the AR may play an important role in regulating the molecular events associated with ER(À) class A breast cancers. AR expression is well known in ER( þ ) breast cancer and has been associated with ER(À) breast cancer with apocrine histologic features (Gatalica, 1997; Matsuo et al., 2002; Sapp et al., 2003) . Morphologic evaluation of our ER/PRÀgroup of tumors demonstrated an increased number of cases with strong apocrine morphology in class A tumors compared to class B (70 vs 21%). Although the sample size is small, these results corroborate the findings of Farmer et al. (2005) , who identified a group of breast tumors with expression of AR and AR-related genes and apocrine features. Nonetheless, the functional role of AR in breast cancer is poorly understood. Androgenic effects on the proliferation of breast cancer cell lines are highly variable (Birrell et al., 1995) , an observation not particularly surprising considering the heterogeneity of AR expression in breast cancer and the complexity of AR signaling. Although several breast cancer cell lines appear to be growth inhibited by the addition of androgens, many are growth stimulated and may be androgen dependent (Lippman et al., 1976; Greeve et al., 2004) . In MCF-7 ER( þ ) breast cancer cells, AR may interfere with ER signaling, leading to a partial G1-S cell cycle arrest and an associated decrease in cell proliferation (Greeve et al., 2004; Buchanan et al., 2005) . In agreement with our results, previous studies have reported AR-dependent androgen-induced proliferation in ER(À) class A MDA-MB-453 cells (Hall et al., 1994; Birrell et al., 1995) . Our data further suggest that this proliferative response is associated with a hormonally regulated transcriptional program that is common to ER(À) class A breast cancers and overlaps with ER-induced transcription in ER( þ ) tumors. However, the overlap is incomplete, and this may reflect the fact that an integrated network of signaling pathways regulates cell proliferation, which AR activation alone does not replicate. We speculate that AR may act in concert with other signal transduction pathways to contribute to the ER(À) class A molecular phenotype. For example, it is well known that receptor tyrosine kinase pathways function as modulators of nuclear hormone receptor activity (Shao and Lazar, 1999) and in this regard it is interesting that ERBB2 is differentially expressed in a proportion of ER(À) class A breast cancers. ERBB2 has been shown to stabilize AR protein levels and optimize binding of AR to promoters of androgen-regulated genes in prostate cancer cells (Mellinghoff et al., 2004) . In the ER(À) class A breast cancer line MDA-MB-453, blocking ERBB2 with PKI166 inhibits PI3K signaling, deactivates mTOR and decreases cell proliferation . Given the proliferative effect of androgen on MDA-MB-453 that we have shown, the potential for cooperative crosstalk between ERBB2 signaling and AR deserves further study. In addition, the anti-proliferative effect of anti-androgens on MDA-MB-453 provides the rationale for study of anti-androgens to treat ER(À) class A breast cancer.
The expression of ERBB2 represents a biologically and clinically important feature of breast cancer, and a molecular subtype characterized by ERBB2 overexpression has been proposed (Perou et al., 2000) . Our observations suggest heterogeneity within the ERBB2 molecular subtype. Indeed, ERBB2 overexpression exists in estrogen responsive, ER( þ ) breast cancer as well as ER(À) breast cancer. Results of unsupervised hierarchical clustering of 99 primary tumors revealed expression of ERBB2 among several sample clusters, and suggested that the expression of ERBB2 alone does not capture the molecular phenotype of class A breast cancer. Indeed, among the class A samples in our data, only 30% were ERBB2 positive. Furthermore, SKBR-3 cells have ERBB2 gene amplification and protein overexpression (Lacroix and Leclercq, 2004) , and were identified by our predictor as class B. Not surprisingly, the ERBB2 monoclonal antibody trastuzumab inhibits the growth of SKBR-3 cells (Mayfield et al., 2001; Yakes et al., 2002) . MDA-MB-453 cells are not ERBB2-amplified and are resistant to the anti-proliferative effects of trastuzumab (Yakes et al., 2002) . Further investigation into the diversity of ERBB2 signaling among various breast cancer subtypes is required.
FGFR4 is another signaling molecule that may cooperate with AR and ERBB2 to drive tumor growth in the ER(À) class A subtype of ER(À)/PR(À) breast cancer. FGFR4 is overexpressed in ER(À) class A tumors and gene amplification may exist in as many as 30% of all breast cancers (Dickson et al., 2000) . In MDA-MB-453 cells, FGFR4 and ERBB2 have been shown to work in concert to activate the mTOR translational pathway and regulate cyclin D1 levels . Simultaneous inhibition of both pathways had a stronger anti-proliferative effect than either alone. In addition, FGFR4-dependent activation of the MAPK/ERK1/2 signaling cascade can drive cell proliferation via downstream initiation of cyclin D1 transcription . This convergence of data suggests that further investigation into the role of FGFR4, ERBB2 and AR in ER(À) class A breast cancers is warranted and that this molecular complex may provide useful therapeutic targets for as many as 25% of ER(À)/PR(À) breast cancer patients.
Materials and methods
Samples and gene expression analysis
Tissue samples were obtained from therapeutic or diagnostic procedures performed as part of routine clinical management at Memorial Sloan-Kettering Cancer Center. All research procedures using human tissue were approved by the MSKCC institutional review board. Tissues were snap-frozen in liquid nitrogen and stored at À801C. Each sample was examined histologically using hemotoxylin-and eosin-stained cryostat sections and enriched for areas of interest by manual trimming of tissue blocks. Total RNA was extracted from frozen tissue by homogenization in guanidinium isothiocyanate-based buffer (Trizol; Invitrogen, Carlsbad, CA, USA), purified using RNAeasy (Qiagen, Valencia, CA, USA) and examined for quality using denaturing agarose gel. Complementary DNA was synthesized from RNA using a T7-promoter-tagged oligodT primer. RNA target was synthesized from cDNA by in vitro transcription, and labeled with biotinylated nucleotides (Enzo Biochem, Farmingdale, NY, USA) (Holzbeierlein et al., 2004) . Gene expression analysis was performed using HG-U133A oligonucleotide microarrays according to the manufacturer's instructions (Affymetrix, Santa Clara, CA, USA). Data files for gene expression analysis are available at http:// caarraydb.nci.nih.gov/caarray/. There were 99 primary breast tumors analysed (77 invasive ductal carcinoma, 10 invasive lobular carcinomas, seven mixed lobular and ductal carcinomas, four metaplastic carcinomas and one not specified). All ER(À)/PR(À) tumors were designated invasive ductal or invasive lobular type. Morphological examination was performed by an experienced surgical pathologist in a blinded manner with special attention to apocrine features. A score was assigned based on the presence of (1) abundant eosinophilic and granular cytoplasm, (2) vesicular nuclei with prominent nucleoli and (3) apical snouts (Miller et al., 1985) . A score of 0 represented no apocrine features, whereas 1 and 2 were reserved for moderate and marked degree of apocrine differentiation, respectively.
Data analysis
Signals were quantified using Affymetrix Microarray Suite 5.0 and expression values were scaled to have a mean expression of 500 across the central 96% of values for each array. Each sample was individually characterized by both probe set intensity values and associated clinical data. A master gene table was compiled, in which specific genes represented by GenBank accession numbers were identified for each probe set (http://www.affymetrix.com). Annotation information corresponding to the GenBank accession number for each probe set was retrieved from the GenBank, LocusLink, Unigene and Gene Ontology Consortium databases. All annotation information was downloaded through the Silicon Genetics Mirror server using the GeneSpider tool (GeneSpring, Silicon Genetics, Redwood City, CA, USA).
Before unsupervised analyses, the gene expression measurements were filtered and normalized using the following methods. We included probe sets that varied the most across samples. Additionally, a probe set was included only if >10% of its measurements exceeded the per chip mean of 500. For each array, probe set values were log 2 transformed and centered to median ¼ 0. Normalization was performed so that all measurements for that array were multiplied by a scaling factor S such that the sum of the squares of the values equaled 1. Each probe set measurement was centered and normalized across samples according to the same procedure. Filtering and normalization were performed independently for each analysis.
Two-way unsupervised hierarchical clustering was performed using the software Cluster 3.0 (de Hoon et al., 2004) and GeneSpring. To cluster data, we used an uncentered standard correlation (Pearson correlation around zero) as our measure of similarity. In constructing dendrograms, centroid linkage was used as the measure of proximity between clusters. PCA was performed using GeneSpring. Principal components were calculated for a designated set of genes and samples, and the three principal components representing the greatest variance in expression were plotted in order to visualize samples in three-dimensional gene expression space.
To identify differentially expressed genes between two groups, we used two different measures: fold change (ratio) between the normalized means of each group of samples and a Student's t-test. For gene expression data generated from cultured cells exposed to different treatments, the data were filtered to include only probe sets with an absolute expression value greater than 200 in at least one condition and differential expression was evaluated by fold change between different conditions.
To evaluate whether two gene lists contained a statistically significant number of overlapping genes, Fisher's exact test was used to calculate the hypergeometric probability of overlap between a specified list and a random list sampled from all genes. The resulting P-value was adjusted with a Bonferroni multiple testing correction.
To evaluate whether members of an a priori defined gene list were correlated with a specific tumor class, a modified KS analysis was performed as described (Subramanian et al., 2005) . Briefly, all 22 215 probe sets were first ranked according to the correlation between their expression and the class A designation. An enrichment score (ES) was then generated, which reflects the degree to which the members of the specified gene list were over-represented toward the top or bottom of the 22 215 ranked probe sets. The ES is analogous to a weighted KS statistic. To determine significance, the ES was recalculated with 1000 randomly permuted class labels to create a null distribution. A P-value for the observed ES was then calculated by comparing the observed ES to this null distribution.
Immunohistochemistry
Immunohistochemical detection was performed using streptavidin-biotin-peroxidase and microwave antigen retrieval methodology as described (Holzbeierlein et al., 2004) . Tissue blocks with multiple samples were prepared using a tissue arrayer (Beecher Instruments, Sun Prairie, WI, USA). For each sample, three 0.6 mm core sections of tissue were extracted from diagnostic areas of formalin-fixed, paraffinembedded tissues. We defined Her2 positivity as 3 þ by IHC, or 2 þ by IHC with gene amplification of 2.1 or greater. Amplification was measured by fluorescence in situ hybridization as described (Lal et al., 2005) . For ER, PR, AR, ERb and FOXA1, samples were considered positive if greater than 10% of cell nuclei were immunoreactive. Fisher's exact test was used to compare the proportions of positive samples among independent groups. Semiquantitative analysis of ER expression was performed using whole sections obtained from the original paraffin-embedded tissue samples. Signal intensity was graded on a scale of 0-3. A final IHC score was computed by multiplying the percent of positive nuclei by the intensity. The magnitude of the difference in IHC score between groups was evaluated using the Mann-Whitney test. For a given gene, the correlation between IHC score and probe set intensity was calculated using Spearman's rank correlation coefficient. Estimates of sensitivity and specificity for predicting ER(À)/ PR(À) class using ALCAM and SPDEF IHC scores were calculated with a receiver-operator characteristic curve using Graphpad Prism (Graphpad Software, San Diego, CA, USA).
Cell culture
The breast cancer cell lines MDA-MB-453, MDA-MB-231, SKBR-3, HCC-1937, ZR75-1, MCF7, BT-474 and T-47D were obtained from American Type Culture Collection (Rockville, MD, USA) (http://www.atcc. org). Cells were maintained at 37 o C in a humidified atmosphere containing 5% CO 2 , in 75 cm 2 flasks containing minimal essential medium (MEM) supplemented with 10% fetal bovine serum, 2% L-glutamine, non-essential amino acids (NEAA), 1 mM sodium pyruvate, 1.5 g/l sodium bicarbonate, 100 IU/ml penicillin and 100 mg/ml streptomycin. Cells were passaged every 3-4 days when they reached 80% confluence, and harvested with 0.25% trypsin/EDTA.
For cell proliferation studies, cells were pelleted by centrifugation and resuspended in medium containing phenol red-free MEM supplemented with 10% charcoal-stripped fetal bovine serum (Hyclone, Logan, UT, USA), 2% L-glutamine, NEAA, 1 mM sodium pyruvate and 1.5 g/l sodium bicarbonate. Cells were plated in replicates of six at a density of 1 Â 10 4 cells/well in 96-well microtiter plates. At 24 h after seeding, cells were treated with various reagents and media and reagents were replenished every 3 days. Reagents used were 10 nM E2 (Sigma-Aldrich, St Louis, MO, USA), 0.1-10 nM R-1881 (Sigma-Aldrich, St Louis, MO, USA), 10 mM flutamide (Sigma-Aldrich, St Louis, MO, USA), 100 nM 4-OHT (tamoxifen) (Sigma-Aldrich, St Louis, MO, USA) and 100 nM anti-estrogen ICI 182,780 (fulvestrant, ICI) (Tocris, Ellisville, MO, USA). Cell viability and proliferation were measured using the 3-(4,5 dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide colorimetric assay (American Type Culture Collection) (Mosmann, 1983) and quantified by measuring absorbance at 570 nm (Victor V7 microplate reader, Perkin-Elmer, Wellesly, MA, USA).
Genome-wide expression profiling was performed for MDA-MB-453 cells in six experimental conditions that included incubation with combinations of androgen, AR antagonist and vehicle control. The six expression time-course experiments, referred to as experiments I-VI, were performed simultaneously. Cells were grown to confluence in one 125 cm 2 flask, trypsinized, resuspended and seeded in six 75 cm 2 flasks at a density of 1 Â 10 6 cells per flask. Cells were then incubated in media containing 10% FBS until 60% confluence, washed with ice-cold PBS and treated with media and reagents according to the six experimental conditions. Experiment I incubated cells in media containing 10% FBS; experiment II used charcoal-stripped media supplemented with vehicle control; experiment III used stripped media with 1 nM R-1881; experiment IV used stripped media with 1 nM R-1881 and 10 mM flutamide. For experiments I-IV, RNA was extracted after 48 h. In experiments V and VI, cells were incubated in stripped media for 48 h and then exposed to either 1 nM R-1881 (V) or vehicle control (VI) for 48 h followed by RNA extraction.
Identification of ERE and ARE motifs
For each probe set, GenBank accession numbers identified specific genes. We retrieved 9999 bp of sequence 5 0 to the start of the transcription site for all genes from the ENSEMBL database using build NCBI 34 (Version 2), updated February 2004, from the Silicon Genetics website (http://www.silicongenetics.com/Downloads/HumanGenome9999.zip). For genes of interest, sequence within 1-5000 bp upstream of the transcription site was analysed for homology to the ERE consensus 5 0 -GGTCAnnnTGACC-3 0 and the ARE consensus 5 0 -AGAACAnnnTGTTCT-3 0 . We allowed for two single point discrepancies in each sequence homology analysis. For genes identified as having putative regulatory sequences, a false positive probability was estimated by observing both the frequency of the regulatory sequence upstream of all other genes and the frequency of the regulatory sequence within a random distribution of bases. In the latter case, the percent occurrence of each base in the random distribution was set to equal the percent occurrence of each base within the sequence in question. Genes with homologous response elements were reported if the higher P-value obtained from these two observations was less than 0.0001.
Class prediction
A prediction algorithm was developed in order to identify samples that expressed a relevant gene signature. Tissue samples were assigned to a subclass based on our unsupervised hierarchical clustering of ER(À)/PR(À) tumors. Differentially expressed genes between the two clusters (designated classes A and B) were ranked by Student's t-test and those with a Pvalue o0.0001 were selected for use in the prediction model. The expression of each predictor gene was used to classify unknown samples using the k-nearest neighbors method (Golub et al., 1999) . Based on normalized expression values, we examined 11 samples near (as measured in Euclidian distance) the unclassified samples, and for each class, computed a P-value of the likelihood of finding the observed number of this class among the identified neighborhood members by chance, given the proportion of class membership in the training set. The class with the lowest P-value was assigned to the unclassified sample. We specified a P-value cutoff of 0.15, so that if there was not sufficient evidence in favor of a particular class, no prediction was made. The Pvalue cutoff is a ratio of the P-value of the predicted class to the alternate class.
